CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Impact of Lesion Preparation Strategies on Outcomes of Left Main PCI: The EXCEL Trial From organic and inorganic phosphates to valvular and vascular calcifications Sex differences in left main coronary artery stenting: Different characteristics but similar outcomes for women compared with men Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced The Year in Cardiovascular Medicine 2020: Valvular Heart Disease: Discussing the Year in Cardiovascular Medicine for 2020 in the field of valvular heart disease is Professor Helmut Baumgartner and Dr Javier Bermejo. Mark Nicholls reports
|<<... 101 102 103 104 105 106 107 ...>>|

Clinical Trial2020 Nov 11.

JOURNAL：Circulation. Article Link

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial

SD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al. Keywords: cardiorenal outcomes; empagliflozin

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top